AKT1 is mutated in 0.88% of malignant solid tumor patients [3].

AKT1 is an inclusion criterion in 16 clinical trials for malignant solid tumor, of which 13 are open and 3 are closed. Of the trials that contain AKT1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 7 are phase 2 (7 open) [4].

Capivasertib, fulvestrant, and olaparib are the most frequent therapies in malignant solid tumor trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 4.96% of breast carcinoma patients [3].

AKT1 is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 7 are open and 1 is closed. Of the trials that contain AKT1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].

Fulvestrant, capivasertib, and akt 1/2 inhibitor bay1125976 are the most frequent therapies in breast carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.01% of non-small cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain AKT1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

Selumetinib, akt inhibitor mk2206, and vistusertib are the most frequent therapies in non-small cell lung carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 3.11% of endometrial carcinoma patients [3].

AKT1 is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in endometrial carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

Pi3k/mtor inhibitor ly3023414, ulixertinib, and x-396 are the most frequent therapies in non-hodgkin lymphoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.51% of squamous cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in squamous cell lung carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.45% of head and neck squamous cell carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

Abemaciclib, alpelisib, and durvalumab are the most frequent therapies in head and neck squamous cell carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.05% of prostate carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

Capivasertib, enzalutamide, and everolimus are the most frequent therapies in prostate carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain AKT1 status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in cancer trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 2.01% of thyroid gland carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 2.67% of thymic carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.37% of gastric adenocarcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is mutated in 1.06% of colorectal carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in colorectal carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.08% of melanoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in melanoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.09% of glioblastoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Atezolizumab and ipatasertib are the most frequent therapies in glioblastoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.13% of small cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in small cell lung carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 1.04% of lymphoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in lymphoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 0.58% of cholangiocarcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Vistusertib, adavosertib, and capivasertib are the most frequent therapies in cholangiocarcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 0.58% of renal cell carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in renal cell carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is mutated in 0.31% of hepatocellular carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is mutated in 0.3% of pancreatic carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in pancreatic carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414 is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in ovarian carcinoma trials with AKT1 alterations as inclusion criteria [4].

AKT1 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in peritoneal mesothelioma trials with AKT1 alterations as inclusion criteria [4].